About FDALive
FDALive.com Pricing Information
Videoconferencing: $1800
Audioconference: $400
Webcast:
· Single Viewer $140 - $250
· Group $800 - $1,200
CD-ROM:
· DPi (Image of Slides on CD): $400.00 for each meeting day purchased.
· DPv (Interactive Video CD): $500.00 for each meeting day purchased.
· DPvi (Interactive Slides & Video): $1,000.00 for each meeting day purchased.
DVD Format:
· $400 for 1 meeting day purchased.
· $800 for 2 meeting days purchased.
· $1,200 for 3 meeting days purchased.
Transcripts:
3 Business Day Services: $1800 - $2200
Group and Volume Discount Rates Available…
Contact for Quote…
Upcoming Meetings
Obstetrics and Gynecology Devices Panel
Meeting Date: 2/12/19-2/12/19
Meeting Details:
On February 12, 2019, the Committee will discuss and make recommendations regarding the safety and effectiveness of surgical mesh placed transvaginally in the anterior vaginal compartment to treat pelvic organ prolapse. FDA is convening this meeting to seek expert opinion on the evaluation of the risks and benefits of these devices. The Committee will be asked to provide scientific and clinical input on assessing the effectiveness, safety, and benefit/risk of mesh placed transvaginally in the anterior vaginal compartment, as well as identifying the appropriate patient population and physician training needed for these devices.
| Location: | Gaithersburg MD | Related News Links: | Not Available |
| Time: | 8:00AM-6:30PM | ||
| Materials: | |||
Recent Meetings
Endocrinologic and Metabolic Drugs AdComm - Sponsor: Sanofi-Aventis US,LLC
Meeting Date: 1/17/19-1/17/19
Meeting Details:
The Committee will discuss new drug application 210934 for sotagliflozin oral tablet, sponsored by Sanofi-Aventis U.S., LLC, for the proposed indication: Adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes mellitus.
| Location: | FDA Meeting Room | Related News Links: | Not Available |
| Time: | 8:00AM-5:00PM | ||
| Materials: | |||
- Bone, Reproductive and Urologic Drugs AdComm - Sponsor: Amgen
Meeting Date: 1/16/19-1/16/19
Meeting Details:
The committee will discuss biologics license application 761062, romosozumab injection, submitted by Amgen, for the proposed indication of treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant of other available osteoporosis therapy.
| Location: | FDA Meeting Room | Related News Links: | Not Available |
| Time: | 8:00AM-5:00PM | ||
| Materials: | |||
- Joint Arthritis & DSRM AdComm - Sponsor: Takeda Pharmaceuticals
Meeting Date: 1/11/19-1/11/19
Meeting Details:
The committees will discuss supplemental new drug application (sNDA) 021-856, ULORIC (febuxostat) tablets, sponsored by Takeda Pharmaceuticals, which includes the results from the postmarketing safety trial required by FDA to evaluate the cardiovascular safety of febuxostat, entitled “Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES).” Febuxostat is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout. The committees' discussion will include the results from the CARES trial, the benefit risk assessment of febuxostat, and potential regulatory actions.
| Location: | College Park Marriott Hotel | Related News Links: | Not Available |
| Time: | 1:00AM-1:00AM | ||
| Materials: | |||
Past Meetings
Below is a listing of all committees. Select a committee to display all meetings available for that committee.
Live Meetings
There are no Live Broadcasts available at this time.
Sign in to FDALive
My Shopping Cart
FDA
FDA
About FDALive